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Abstract
Background: Metastasis is the major cause of death in breast cancers. MMPs play a key role in tumor
microenvironment that facilitates metastasis. The existing researches suggest that the high expression of gelatinase
A and B (MMP2 and MMP9) promote the metastasis of breast cancer. Therefore, gelatinase inhibitor can effectively
suppress tumor metastasis. However, at present, there is no dramatically effective gelatinase inhibitor against breast
cancer.
Methods: We screened gelatinase inhibitor among Chinese herbal medicine by molecular docking technology;
investigated the proliferation, migration and invasion of MDA-MB-231 human breast cancer cell line and 4T1 mouse
breast cancer cell line in response to the treatment with the screened inhibitor by wound assay, invasion assay and
gelatin zymography; then further examined the effects of inhibitor on allograft mammary tumors of mice by
immunohistochemistry.
Results: We successfully screened an Chinese herbal medicine-Plantamajoside(PMS)-which can reduce the
gelatinase activity of MMP9 and MMP2. In vitro, PMS can inhibit the proliferation, migration and invasion of
MDA-MB-231 human breast cancer cell line and 4T1 mouse breast cancer cell line by decreasing MMP9 and MMP2
activity. In vivo, oral administration of PMS to the mice bearing 4T1 cells induced tumors resulted in significant
reduction in allograft tumor volume and weights, significant decrease in microvascular density and significant lower
lung metastasis rate.
Conclusions: Our results indicate that as a promising anti-cancer agent, PMS may inhibit growth and metastasis of
breast cancer by inhibiting the activity of MMP9 and MMP2.
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Background
Breast cancer is the most common type of malignant
disease in women worldwide. In the past two decades
the mortality rate in breast cancer patients has been
decreasing thanks to the development of early diagnostic
methods and more effective treatments. However, breast
cancer is still the second leading cause of cancer-related
deaths in women [1], the main reason for that is the
metastasis. As Christopher R.bohl pointed out, the most
deadly attribute of breast cancer cells is their ability to
leave their initial site of growth, travel to discontinuous
secondary sites, and proliferate into macroscopic masses
[2]. What’s more, conventional treatments (e.g. chemo-
therapy, radiotherapy and surgery) can cure primary
tumors, but cannot control the secondary tumors. Many
breast cancer patients suffer relapse and metastasis after
treatment [3]. The metastasis of primary tumors depends
not only on the characteristics of cancer cells themselves,
but also the formation of proper environments, which is
named as “metastatic niche”. New metastases couldn’t
generate before the “pre-metastatic niche” developing into
“metastatic niche” [4]. Therefore, in order to cure breast
cancer, the mechanism of its metastasis must be fully
understood to facilitate the establishment of methods to
suppress the metastasis.
Matrix metalloproteinase 9 (MMP9) and Matrix metal-
loproteinase 2(MMP2) show a stronger expression in
breast cancer tissue compared to that in normal breast
tissue [5]. MMP9 expresses activity to degrade the extra
cellular matrix (ECM) in the vicinity of tumor, which has
close relationship with the invasion and metastasis of tu-
mors. The previous research has proved that MMP9 plays
a key role in the process of formation of “metastatic niche”
and regulates pulmonary metastasis via over expression
[6]. MMP9 is treated as a “general commander” of ECM
remodeling, in charge of the final degrading of collage-
nous fiber, releasing tumor cells from the surrounding
complicated network. Take mammary gland tissue for in-
stance, collagen composed the major part of connective
tissue, its degradation includes two steps—collagenases
disintegrate the whole fiber into tiny fragment which can
denatured into gelatin, then MMP9 decomposed these
gelatins [7].
Mounting researches have shown that MMP9 in serum
and tissue can serve as a prognosis biomarker for tumors
[8, 9]. The significant overexpression of MMP9 in serum
associates with lymph nodes metastasis, higher staging,
shorter disease-free time and overall survival time [8, 9].
Human breast cancer cell-produced MMP9 is specifically
required for invasion in cell culture and for pulmonary
metastasis in a mouse orthotopic model of basal-like breast
cancer. MMP9 may offer a target for anti-metastatic
therapies for basal-like triple negative breast cancers
[10]. MMP-2, MMP-9 and eukaryotic transcription
factor-1(ETS-1) co-expression might be used as a poor
prognostic factor in breast cancer patients [11]. Stromal
MMP-2 expression may play a crucial role in predicting
aggressive clinical behavior in breast cancer patients
[12]. MMP-2 in stromal fibroblasts might indicate poor
survivors in patients with high grade breast cancer [13].
MMPs are not only a prognosis factor for breast cancer,
but also a potential treatment target. There are lots of
surveys on regulation of MMPs. In the past few de-
cades, the research about MMP inhibitors (MMPIs) in
tumor treatment has developed rapidly. The third gen-
eration MMPIs is under the clinical research currently.
The third MMPIs mainly target on some special MMPs,
like MMP9 and MMP2. The original concept that
MMPs are just ECM remodeling regulator has been
taken place by new concepts that MMPs are proteinase
which can regulate the functions of various protein
[14]. Furthermore, the substitutes and products of
MMPs can also been seen as the target of cancer treat-
ment. All of these researches on cancer treatments
must depend on the profound understanding of the role
of MMPs in tumor microenvironment, tumor growth
and metastasis.
Since MMP9 and MMP2 regulate tumor microenviron-
ment and tumor metastasis, in theory, the invasion and
metastasis of tumor can be inhibited through decreasing
the activity of MMP9 and MMP2. Nowadays, more and
more traditional Chinese medicines (TCMs) are applied in
the prevention and treatment of many different kinds of
tumors. We have particular advantages of accessing to
TCMs, because medicine resource in China is abundant.
There are more than 12,800 medical animals and plants
TCMs, which provide a wide choice for new anti-tumor
drug screening [15]. Docking calculations has been apply-
ing in medical research for more than 20 years. Computa-
tional approaches that ‘dock’ small molecules into the
structures of macromolecular targets and ‘score’ their
potential complementarity to binding sites are widely used
in hit identification and lead optimization [16]. Plantama-
joside(PMS) was selected by combining MMP9 through
Docking calculation.
PMS is an extract from Herba Plantaginis, a conventional
TCM, with the role of antiviral, diuretic, antioxidant and
immune enhancement [17]. It’s been used in medicine and
food in a long term. Herba Plantaginis contains polyphe-
nols, mainly phenylpropanoid glycosides and flavonoids.
PMS is a unique component for identification of Herba
Plantaginis, belongs to phenylpropanoid glycoside. A study
showed that the PMS concentration of the peak blood
plasma of rat after oral administration was 172.3 ± 35.1 ng/
mL, the required time was 16.7 ± 2.8 min [18]. Other stud-
ies have indicated that PMS has the antioxidant effect and
has the protective effect on the kidney damage caused by
cadmium [19]. Despite this, there are no reports of anti-
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tumor studies on PMS. Since PMS can target combine with
MMP9 and MMP2, we assumed that PMS could suppress
the growth and metastasis of breast cancer via regulating
the activity of MMP9 and MMP2.
Methods
Chemical
Plantamajoside (PMS) and other ten agents (Catechin,
Chrysophanol, Phlorizin, Salidroside, Curcumin, Isoac-
teoside, Silymarin, Echinacoside, Gastrodin, Harpago-
side) were purchased from CHENGDU MUST BIO-
TECHNOL CO., LTD(Sichuan, China), ≥98 %, dissolved
in solution with equal proportion of ethanol and ultra-
pure water when administrated. The chemical structure
of Plantamajoside is shown in Fig. 1a.
MMP activity inhibition in vitro
The affinity of all 11 agents with MMP9 and the affinity
of PMS with MMP2 were evaluated through molecular
docking technology according to Docking calculations
by SwissDock software (Swiss Institute of Bioinformatics,
Lausanne, Switzerland). The lower binding free ener-
gy(ΔG) is, the stronger combining ability is. Enzyme
inhibition test in vitro was performed to detect the in-
hibition effect of 11 agents on MMP activity. Load 50 μL
of 0.4 ng/μL activated Recombinant Human MMP9
(rhMMP9) (Catalog # 911MP,R&D system,Inc. U.S.A) or
MMP2(Catalog # 902MP,R&D system,Inc. U.S.A) and
50 μL of 20 μM Substrate (MCAProLeuGlyLeuDPAAla-
ArgNH) (Catalog#ES001,Catalog # 911MP,R&D system,
Inc.U.S.A) into Black Maxisorp Plate(Nunc, Catalog #
475515, Dermar-k) with solvent (Control) or with 100 μg/
mL of each agent to start reaction. Triplicated wells were
used for each group. Read the absorbance [present as op-
tical density (OD)] at excitation and emission wavelengths
of 320 and 405 nm on Fluorescent Plate Reader (MD
spectra-max m5, Molecular Devices, U.S.A). The activity of
MMP9 was direct proportional to OD.
Cell culture
MDA-MB-231(ATCC® HTB-26™) human breast tumor
cell line and 4T1 (ATCC® CRL-2539™) mouse breast
tumor cell line were purchased from ATCC (American
Type Culture Collection, Manassas, VA, USA). Chinese
Hamster Ovary (CHO-K1)(Cell bank of Chinese Acad-
emy of Science, Beijing, China) . MDA-MB-231 cells
and 4T1 cells were grown in DMEM(gibco, life tech-
nologies, China) medium or RPMI-1640 (gibco, life tech-
nologies, China)medium respectively supplemented with
10 % fetal bovine serum (FBS, gibco, life technologies,
China),and penicillin(100units/mL) and streptomyci-
n(100units/mL) incubated at 37 °C in a 5 % CO2 –95 %
air environment. CHO cells were cultured in the same

























Fig. 1 Plantamajoside(PMS) affects the activity of MMP9 and MMP2. a A diagram of the structure of PMS(PubChem CID:5281788). b The
molecular docking of PMS to MMP9 and MMP2. We can see the PMS molecule (indicated with red arrow) combined with MMP9 or MMP2, and
the minimum ΔG (circled in red square)value were -10.39 and -9.51 kcal/mol respectively. c Detected IOD of substrate activated by MMP9 and
MMP2 treated with solvent or PMS. Data represent the mean ± S.D. of three independent experiments. The *** indicates extremely
significance different
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Cell growth evaluation
Cell viability assay was performed by planting cells (both
MDA-MB-231 cells and 4T1 cells) in 96-well microplate
at a density of 1 × 104 cells/well for 24 h before attached.
Then cells were divided in different groups including
control group (solvent without PMS) and groups treated
with various doses of PMS or Catechin. Triplicated wells
were used for each group. Cell viability was assessed
with Cell Counting Kit (CCK-8, Beyotime, Shanghai,
China.) at 0, 12, 24, 36, 48 h post-treatment according to
the manufacturer’s instructions. To determine the cell
viability, OD450 (the absorbance value at 450 nm) was
read with 96-well plate reader (ELx808 Absorbance
Reader, BioTek. China). Cell viability assay was also per-
formed on CHO cells to investigate the side effect of
PMS on normal cells. The PMS concentration closed to
IC50 (data not shown) for MDA-MB-231 cells and 4T1
cells at 36 h time point was chosen to treat CHO.
For the colony formation assay, properly resuspend cells
were randomly plated in 6-well plate at a density of 1 ×
104 cells/well with solvent without PMS (Control) or with
100 μg/mL PMS or Catechin. Triplicated wells were used
for each group. After 36 h treatment, washed out the cell
debris and nonattached cells, added fresh medium without
PMS into all of the wells, followed by 10-day incubation.
The attached cells were stained with 0.1 % (W/V) crystal
violet (Solarbio, Beijing China).
Migration assay
Wound assay was performed to evaluate the migration
ability of cells. Cells were seeded in 6-well plate and
grew to confluence followed by scratching the mono-
layer cells with a 200 μL pipette tip to create wound.
Plates were washed to remove floating cells and debris
and then incubated with medium with solvent without
PMS (Control) or with 200 μg/mL PMS or Catechin.
Triplicated wells were used for each group. Photo-
graphed the cells migration images at 0, 36 h. Open
wound area (percentage of an image that is not covered
by cells) was calculated with the TScratch software(-
Computational Science & Engineering Laboratory, Zur-
ich, Switzerland).
Invasion assay
8 μm pore-size tanswell filters(Costar, Corning Incorpo-
rated, U.S.A) were put in 24-well plate and the upper
chambers were covered with BD Matrigel Matrix(B-
D,U.S.A), then cells were seeded onto the filters at a
concentration of 1 × 104 cells/well in 100 μL of FBS free
medium with solvent without PMS (Control) or with
different concentration of PMS or Catechin. The lower
chambers were filled with 600 μL of medium with 10 %
FBS. Triplicated wells were used for each group. After
36 h of treatment, cells on the topside of the filter were
removed by scrubbing with a tipped swab. The migra-
tion of cells to the lower side of the filter was deter-
mined by crystal violet staining. To investigate the
relevant of the inhibition effects of PMS in MMPs activ-
ity and tumor invasion, exogenous MMP9 (Catalog #
911MP,R&D system,Inc. U.S.A) contained in fresh media
was added to the wells treated 36 h with PMS. After
36 h treatment of exogenous MMP9 at the concentra-
tion of 200 ng/mL, the consequent tests described above
were performed.
Gelatin zymography
Cells were randomly plated in 6-well plate at a density of
2 × 105 cells/well with solvent without PMS (Control) or
with 125 and 250 μg/mL PMS or with 100 and 200 μg/mL
Catechin. Triplicated wells were used for each group. After
24 h or 36 h treatment, washed the cell monolayer with
sterile Phosphate Buffered Saline (PBS) to remove the
serum completely. Then incubated the cells in serum-free
media at 37 °C in a Carbon dioxide (CO2)incubator for
12 h. The culture media were collected and centrifuged at
14,000 rpm for 10 min at 4 °C,the protein concentration
was determined. Equivalent samples were subjected to
sodium dodecyl sulfate-polyacrylamide gelelectrophoresis
(SDS-PAGE) on 10 % gel which contained 0.1 % w/v gelatin
(Sigma,U.S.A). The gel was removed to renaturing solution
[2.5 % Triton X-100, 50 mmol/LTris-HCl, 5 mmol/L CaCl2
and 1 μmol/L ZnCl2 in distilled water (dH2O)] for 1 h at
room temperature with gentle agitation and then was
rinsed with dH2O completely. Next the gel was incubated
in developing solution (50 mmol/L Tris-HCl, 5 mmol/L
CaCl2, 1 μmol/L ZnCl2 and 0.02 % Brij-35 in dH2O) for
20 h and stained 3 h in staining solution (0.05 % Coomassie
blue RR-250, 30 % methanol and 10 % acetic acid in
dH2O), followed by destained in destaining solution(5 %
methanol and 10 % acetic acid in dH2O) until area of gelati-
nolytic activity appeared as clear sharp bands over the blue
background.
Western blotting
Cells were randomly plated in 6-well plate at a density
of 2 × 105 cells/well with solvent or with 125 and
250 μg/mL PMS. Triplicated wells were used for each
group. After 36 h treatment, cells were harvested and
washed twice with ice-cold phosphate-buffered saline
(PBS, PH 7.4), and lysed with ice-cold lysis buffer
(P0013B, Beyotime, China) for 30 min on ice. The ly-
sates were centrifuged at 12,000 rpm for 5 min at 4 °C,
and the protein concentration was determined. Equiva-
lent samples (20 μg protein extract was loaded on each
lane) were subjected to SDS-PAGE on 10 % gel. The
proteins were then transferred onto polyvinylidene fluoride
(PVDF) membranes (IPVH000 10, MercKMillipore), and
probed with indicated primary antibody, MMP9(ab38898,
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Abcam,1:500), MMP2(sc-13595, Santa Cruz, 1:500) and
GADPH (as loading control, sc-166574, Santa Cruz, 1:500).
Primary antibody was detected by binding horseradish
peroxidase (HRP)-conjugated anti-rabbit or anti-mouse
secondary antibody with an Electro-Chemi-Luminescence
(ECL) plus kit (32109, Thermo, China).
Allograft experiment
The animal study was approved by the Institutional Ani-
mal Care and Use Committee of China Agricultural Uni-
versity. Subcutaneous inoculation of 1.5 × 106 4T1 cells
in 200 μL PBS was carried out in 4-weeks-old BALB/c
mice. The fifth day after inoculation, mice were treated
daily with solvent without PMS (Control) (n = 6) or with
PMS (n = 6) at 200 mg/kg body weight by oral delivery.
After 21-day treatment, all mice were euthanized for col-
lection of allograft tumors and lungs.
Immunohistochemical analysis
4T1 allograft tumors and lung tissues were dissected and
fixed in 10 % (v/v) neutral-buffer formalin for 24 h. The
fixed tissues were dehydrated in ascending grades of etha-
nol and xylene, and then embedded in paraffin wax. Sec-
tions (3 μm) were cut with microtome (Leica, Germany)
and mounted on CITOGLAS ® adhesion microscope slides
(CITOTEST, Jiangsu, China). Immunostaining was per-
formed by using antibodies for the proliferation marker
protein -antigen identified by monoclonal antibody Ki-67
(Ki67) (ZSGB-BIO, Beijing, China), cluster of differenti-
ation 31(CD31) (Bioss, Beijing, China 1:150). The biotinyl-
ated secondary antibody was goat anti-rat and anti-rabbit
antibody IgG (ZSGB-BIO, Beijing, China). The slides were
firstly stained with diaminobenzidine (DAB) and then
counter stained with hematoxylin. The stained slides were
dehydrated and mounted coverslips with neutral glue.
Images were captured and analyzed by Image-pro-plus
software (Media Cybernetics, Washington, USA).
Statistical analysis
Numerical results are expressed as mean ± standard devi-
ation. Treatment effects were compared by analysis of
variance or Student’s t-test (when only 2 groups) and dif-
ferences between means were considered to be significant
when P <0.05. The analyses were performed using SPSS
20 software (Statistical Product and Service Solutions,
Chicago, USA).
Results
PMS dramatically reduced the activity of MMP9 and
MMP2 in vitro
According to Docking calculations by SwissDock software,
PMS can targeted combined to MMP9 (Fig. 1b), the affin-
ity is strongest when ΔG= -10.39 kcal/mol. Other agent
can also combine to MMP9 (Additional file 1: Table S1
and Additional file 2: Figure S1), however the ΔG was
higher than -10 kcal/mol, which means the affinity of
PMS to MMP9 was the strongest among these 11 agents.
PMS can also targeted combined to MMP2, but the ΔG
was higher than -10 kcal/mol too. In order to detect the
inhibition function of these agents towards MMP, enzyme
inhibition test in vitro was performed and the result
(Fig. 1c) shows that the integrated optical density (IOD) of
100 μg/mL PMS treatment (557.0 ± 67.6 or 890.1 ± 82.2)
was significantly lower than that of control group (4499.8 ±
185.9 or 4301.3 ± 211.3)(P <0.01) in MMP9 or MMP2 in-
hibition assay respectively. Therefore, PMS can decrease
the activity of MMP9 and MMP2 by a large mount. The
inhibition effect of other agents (Additional file 2: Figure
S1) are worse than that of PMS.
Cell proliferation decreased significantly after treatment
of PMS
To establish a proper treatment dose of PMS, MDA-MB-
231 cells and 4T1 cells were treated with various doses of
PMS. Cell viability was analyzed using Cell Counting Kit-8
after 0, 12, 24, 36 and 48 h treatment. Cells showed a
decrease in viability with increasing dose, and a correl-
ation was observed with post treatment period (Fig. 2a
and b), decrease of cell viability treated with PMS is dose
and time dependent. PMS shows clear dose and time
dependency in both of these two cell lines. As shown in
Fig. 2c, cell viability has significant decrease after the
250 μg/mL PMS 36 h treatment (P <0.01). CHO cells were
treated with 300 μg/ml PMS for 36 h, and there was no
significant change of cell viability between pre and post
PMS treatment (Additional file 3: Figure S2d), which indi-
cates that PMS has no side effect on normal cells.
Next, the ability of cell colony was evaluated by colony
formation assay. MDA-MB-231 cells and 4T1 cells were
treated with 100 μg/mL PMS. As shown in Fig. 2d, the
crystal violet staining results suggested that PMS re-
markably inhibited colony formation of MDA-MB-231
cells and 4T1 cells.
Cell proliferation decreased significantly after treatment
of Catechin
Catechin is one of the ten agents we screened from. It’s
also an extract from traditional Chinese medicine as well
as PMS. Docking calculation result shows that Catechin
also has affinity to MMP9 (Additional file 1: Table S1),
but in enzyme inhibition test in vitro, Catechin doesn’t
show inhibition effect on MMP9 activity (Additional file
2: Figure S1). So we choose Catechin as the negative
control to PMS in the consequent cell experiments.
MDA-MB-231 cells and 4T1 cells were treated with
various doses of Catechin. Cell viability was analyzed using
Cell Counting Kit-8 after 0, 12, 24, 36 and 48 h treatment.
Cells showed a decrease in viability with increasing dose,
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and a correlation was observed with post treatment period
(Additional file 2: Figure S2 A and B), decrease of cell via-
bility treated with Catechin is dose and time dependent.
The ability of cell colony was evaluated by colony forma-
tion assay. MDA-MB-231 cells and 4T1 cells were treated
with 100 μg/mL Catechin. As shown in Additional file 3:
Figure S2C, the crystal violet staining results suggested
that Catechin remarkably inhibited colony formation of
MDA-MB-231 cells and 4T1 cells.
PMS inhibited cells migration and invasion through down
regulated the activity instead of the expression of MMP9
more than that of MMP2
Since migration of tumor cells across the blood vessel-
lining endothelial monolayers and their invasion through
extra cellular matrix (ECM) play an important role in
the metastatic process, effect of PMS was evaluated on
the migration and invasive behavior of both human and
rodent breast cancer cells.
In the wound assay, PMS caused a decrease in the num-
ber of cells migrating into the wound area in both cell lines
(Fig. 3a). The significant inhibitory effect induced by PMS
at concentration of 200 μg/mL was at 36 h in comparison
with control cells, where wounds were almost completely
healed at this time. PMS inhibited the migration at 36 h by
approximately 79.3(±8.2) %, 56.4(±4.2) % of MDA-MB-231
and 4T1 cells respectively, in comparison with control
groups in which the inhibition rate were 15.8 (±1.5) %, and
33.6(±7.3) % respectively (Fig. 3b). There were significant
differences between control group and PMS treatment
group (P <0.01). However, Catechin shows no effect on the
migration of tumor cells from both cell lines(Additional file
4: Figure S3A). The inhibition rate of Catehcin at 36 h were
approximately 10.7(±0.9) %, 32.5(±4.2) % of MDA-MB-231
and 4T1 cells respectively, in comparison with control
groups in which the inhibition rate were 15.6 (±2.0) %, and
37.1(±5.2) % respectively (Additional file 4: Figure S3B).
There is no statistical significant difference between control
group and Catechin treatment group.
Transwell assays showed that invasion inhibition effect
of PMS on breast cancer cells were dose-dependent
(Fig. 3c). At the concentration of 100 μg/mL, PMS inhib-
ited cell migration by 48.3(±5.0) % in MDA-MB-231 cells
(Fig. 3d) and 5.3(±3.5) % in 4T1 cells (Fig. 3e). Increased
the concentration to 200 μg/mL the inhibition rate reached
to 53 (±8.7) % in MDA-MB-231 cells (Fig. 3d) (P <0.01)
and 36.3(±5.7) % in 4T1 cells (Fig. 3e)(P <0.05). However
Catechin shows no inhibition ability on the invasion of can-
cer cells (Additional file 4: Figure S3). At the concentration
of 100 μg/mL, Catechin inhibited cell migration by 0(±2.6)
% in MDA-MB-231 cells (Additional file 4: Figure S3D)
and 1.3(±3) % in 4T1 cells (Additional file 4: Figure S3E).
Increased the concentration to 200 μg/mL the inhibition
rate were 1(±3) % in MDA-MB-231 cells (Additional file 4:
Figure S3D) and 1.3(±1.5) % in 4T1 cells (Additional file 4:
Figure S3E).
To further detect the relationship between inhibition
of PMS on cancer cell lines and the activity of MMP, the
MDA-MB-231




























































































Fig. 2 Cell viability decreased after treatment of PMS. Cell viability was analyzed using Cell Counting Kit 8 at 0, 12,24,36,48 h after 31.25, 62.5, 125,
250, 500 μg/m L PMS treatment in (a) MDA-MB-231 and (b) 4T1 cells. c Cell viability was detected after 36 h 250 μg/mL PMS treatment. Data
represent the mean ± S.D. of three independent experiments. d Colony formation of MDA-MB-231 and 4T1 cells. Cells were treated with 100 μg/
mL PMS for 36 h, followed with crystal violet staining of attached cells at 10 days. Similar results were obtained from independent experiments.
The *** indicates extremely significance different
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culture media of cells treated with solvent without PMS
(control) or with 125 and 250 μg/mL PMS or 100 and
200 μg/mL Catechin for 24 h and/or 36 h were analyzed
by gelatin zymography assay, the activity of MMP9 was
dramatically decreased by PMS both in MDA-MB-231
cells and 4T1 cells shown as Fig. 3f; the activity of
MMP2 was also decreased, but the decrease was less
than that of MMP9 (Fig. 3f ). However, Catechin has no
effects on the activity of MMP9 and MMP2 shown as
Additional file 4: Figure S3F. These results showed that
PMS primarily inhibited the activity of MMP9 other
than MMP2 to inhibit the migration and invasion of
breast cancer cell lines. However, PMS didn’t change the
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Fig. 3 PMS inhibits migration and invasion of MDA-MB-231 or 4T1 cells by decreasing the activity of MMP insdead of the expression of MMP.
a and b Effect of PMS on cellular migration by wound assay. a Confluent monolayers of cells were culture with solvent and with 200 μg/ mL
PMS and the migration was evaluated by wound assay at 36 h. Scale bar = 100 μm. b The analysis of % open wound area was performed by
the Tscratch software corresponding to the images in a. Data represent the mean ± S.D. of three independent experiments. c–e Effect of PMS
on cellular invasion by transwell assay. c Cells were cultured with solvent or with 100, 200 μg/mL PMS onto the upper well coated with Matrigel.
After 36 h treatment, cells passed though the Matrigel into the lower well were stained and counted. Scale bar = 25 μm (d) and (e) Analysis the
% of invasion in comparison with control cell(100 %) corresponding to the images in c. Data represent the mean ± S.D. of three independent
experiments. f PMS inhibits the activity of MMP9 and MMP2 secreted by MDA-MB-231 and 4T1 cells in vitro. The effect of PMS on MMP9 activity
was tested by in gel zymography assay. Cells were cultured onto 6-well plates with solvent and with 125, 250 μg/mL PMS. After 24 h and/or
36 h treatment, cell supernatant was collected and performed Zymography. g Western Blotting showing the expression of MMP9 and MMP2 after
36 h treatment with solvent or 125, 250 μg/mL PMS. Similar results were obtained from independent experiments. The ** indicates significance
different. The *** indicates extremely significance different
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The invasion inhibition effect of PMS on MDA-MB-231 or
4T1 cells can be rescued by exogenous MMP9
In order to evaluate the relationship between the inhib-
ition ability of PMS on MMP’s activity and tumor cells’ in-
vasion ability, cells were cultured with solvent or with 100,
200 μg/mL PMS onto the upper well coated with Matrigel.
After 36 h treatment, exogenous MMP9 was added to the
PMS treatment well for 36 h, cells passed though the
Matrigel into the lower well were stained and counted
(Fig. 4a). After rescued by exogenous MMP9, at the con-
centration of 100 μg/mL, PMS inhibited cell migration by
3.7(±3.5) % in MDA-MB-231 cells (Fig. 4b) and 1.3(±3) %
in 4T1 cells (Fig. 4c). Increased the concentration to
200 μg/mL the inhibition rate were 3.6(±3.2) % in MDA-
MB-231 cells (Fig. 4b) and 5.3(±2.1) % in 4T1 cells
(Fig. 4c).
PMS suppressed 4T1 allograft tumor in vivo
As PMS inhibited cell proliferation of cancer cell lines
in vitro, we expect it will further suppress tumor
growth in vivo. To confirm it, 4T1 cells were injected
subcutaneously into BALB/c mice to establish allograft
tumors. Then the mice were treated with 200 mg/kg
PMS by oral gavage for 21 consecutive days. As shown
in Fig. 5a, the treatment caused significant tumor sup-
pression. Quantitative analysis displays that the weight
and volume of tumors in treatment group were less
than that in control group (Fig. 5b and c) (P <0.05).
Immunohistochemistry staining of ki67 further con-
formed that tumor growth was synergistically inhibited
(Fig. 5d), and the difference between these two groups
was significant (Fig. 5e).
The antitumor effect of PMS was achieved via decreasing
angiogenesis
4T1 cell line is a malignant rodent breast cancer cell line
which can cause severe lung metastasis. Since PMS
inhibited the growth of the primary tumor by signifi-
cantly reducing the volume and weight of tumors, in
order to further explore the effect of PMS on inhibiting
metastasis, we compared several indicators of pulmonary
metastasis between the control group and PMS treat-
ment group.
The complete lungs were fixed after autopsy and the
number of lung metastases was counted, Fig. 6a shows that
the metastasis foci (arrow) of the control group(92.8 ± 11.9)
were significantly more than those of the PMS treatment





























































Fig. 4 The invasion inhibition effect of PMS on MDA-MB-231 or 4T1 cells can be rescued by exogenous MMP9. a Cells were cultured with solvent or
with 100, 200 μg/mL PMS onto the upper well coated with Matrigel. After 36 h treatment, exogenous MMP9 was added to the PMS treatment well for
36 h, cells passed though the Matrigel into the lower well were stained and counted. Scale bar = 25um. b and c Analysis the % of invasion in
comparison with control cell(100 %) corresponding to the images in a. Data represent the mean ± S.D. of three independent experiments
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differences between the two groups (Fig. 6b) (P <0.01).
Lung tissue were stained by H&E, the lung metastasis in
the control group(69.3 % ± 9.0 %) were much bigger than
those in PMS treatment group (36.0 % ± 7.5 %) (Fig. 6c),
quantitative statistics existed significant differences (Fig. 6e)
(P <0.05). The IHC staining of Ki67 of control group
(24.3 % ± 2.1 %) is significantly more than PMS treatment
group (10.6 % ± 4.5 %) (Fig. 6d and f) (P <0.05).
To further explore the mechanism of PMS inhibition
on tumor lung metastasis, we detected the biomarker of
angiogenesis-CD31 in primary tumor tissues by IHC
staining (Fig. 6g), after IPP software semi quantitative
analysis, there were significant differences between the
two groups (Fig. 6h) (P <0.01)(control vs. PMS is 0.37 ±
0.08 vs.0.19 ± 0.03). It can be inferred that PMS may in-
hibits activity of MMP9 and MMP2 which causes angio-
genesis decreasing, therefore reduces lung metastasis.
Discussions
As potential cancer therapeutic and preventive agents,
herbal medicine is currently becoming more and more
attentive. In a cross-sectional survey, a substantial num-
ber of people with cancer are likely to be taking herbal
medicine [20]. Previous studies proved that anti-cancer
effect of herbal medicine in various tumors: Chinese
herbal medicine Qingyihuaji Formula (QYHJ) could in-
hibit pancreatic cancer cell invasion and metastasis in
part by reversing tumor-supporting inflammation [21];
Ginseng can be used as an anti-cancer agent in the treat-
ment of colorectal Cancer [22]; Withaferin A (WFA)
induces breast cancer growth inhibition [23]. Now more
than 60 herbal complexes are being studied as anti-
cancer medicine. Plant derived anticancer agents in clin-
ical use can be divided into four important groups:
Vinca, Alkaloids, Taxanes, podophyllotoxin [24], so it is
feasible to find new drugs that inhibit the metastasis of
breast cancer from the traditional Chinese herbal medi-
cine. Depending on this standpoint, we firstly screened
PMS targeted binding to MMP9 via docking calculation
(Fig. 1b). PMS, a major effective elements extracted from
Plantago major L, is applied to the treatment of many
diseases, such as its protective activities against Cd-
induced renal injury [15], anti-inflammation effect [25],
anti diabetic effect [26]. Plantago major L has an inhibi-
tory effect on some tumor (In vivo Antitumoral Effect of
Plantago major L. Extract on BALB/C Mouse with Ehr-
lich Ascites Tumor), however which component play the
main role is not clear. We expected that the PMS may
have potential anti-tumor effects.
To demonstrate this prediction, first of all, we evalu-
ated the effect of PMS on cancer cell lines. Our results
show that PMS can inhibit the growth of cancer cells
(Fig. 2) without side effect on normal cells (Additional
file 3: Figure S2d), as well as their ability of invasion and
metastasis, while reducing the MMP9 and MMP2 activ-
ity (Fig. 3). As a negative control, Catechin can also in-
hibit the growth of cancer cells (Additional file 3: Figure
S2A-C), but has no inhibition effects on the migration
and invasion of cancer cells, either the activity of MMP2
and MMP9 (Additional file 4: Figure S3). It indicates
that the dose we choose to treat cells in migration and
invasion assays would not decrease the cell viability.
Therefore, PMS reducing the migration and invasion
ability of cancer cells is not due to the decreasing of cell
viability. Exogenous MMP9 can rescue the invasion
ability of cancer cells that treated with PMS (Fig. 4). So
PMS did inhibit tumor cell proliferation and migration
and invasion activity by decreasing the activity of MMP.
Due to the wide range of MMPs activities in tumor,
there is not an exact conclusion on the mechanism of
MMP promoting metastasis. Some studies suggest that































































Fig. 5 The antitumor effect of PMS treatment in vivo. Mice were
injected s.c. with 1.5 × 106 4T1 cells. a–c The fifth day after the
injection, mice were treated daily with PMS at 200 mg/kg by oral
gavage for 21 consecutive days. a Representative tumors at the end of
the experiment, (b) tumor volume, (c) tumor weight at indicated time
points after treatment was calculated. d Paraffin-embedded sections of
control or treated tumor tissues from mice were analyzed by Ki67 IHC
staining. e Quantitative analysis of Ki67 staining corresponding to the
images in d. Data represent the mean ± S.D. of three independent
experiments. Scale bar = 25 μm. The ** indicates significance different.
The *** indicates extremely significance different
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results in both matrix remodeling and release of chemo-
kines, cytokines and growth factors trapped within the
ECM [27], promoting EMT process-KLF8-to-MMP9
signaling that promotes human breast cancer invasion
[28]. Others argue that it’s involved in regulating other
receptor protein expression-SPARC and MMP9 interact
to regulate tumor metastasis [29].and controlling vascu-
lar formation. Tumor cell-produced MMP9 promotes
vessel formation in an orthotopic allograft model of
basal-like triple negative breast cancer [9]. Obviously,
further study on the concrete mechanism of PMS inhi-
biting tumor via decreasing MMP activity are warrant.
In order to further determine the inhibition of PMS on
tumor in vivo, we carried out tumor inhibition experiments
in vivo. 4T1 cells were chosen to allograft, because the 4T1
tumor is highly tumorigenic and invasive, unlike most
tumor models, can spontaneously metastasize from the pri-
mary tumor in the mammary gland to multiple distant sites
including lymph nodes, blood, liver, lung, brain, and bone
[30, 31], The progressive spread of 4T1 metastases is very
similar to that of human breast cancer. Our study con-
firmed that only 1.5 × 106 cells can bear tumor successfully
(Fig. 5a), and led lung metastasis (Fig. 6a), similar to other




















































































Fig. 6 PMS inhibited tumor metastasis via decreasing angiogenesis. The complete lungs were fixed after autopsy and the number of lung
metastases foci (arrow) was counted (a). b Quantitative analysis of metastases corresponding to the images in a. Paraffin-embedded sections of
control or treated lung tissues from mice were analyzed by (c) H&E staining (Scale bar = 100 μm) and analyzed by (d) Ki67 IHC staining(Scale bar
= 25 μm). e and f Quantitative analysis of metastases or Ki67 staining corresponding to the images in a and b respectively. Data represent the
mean ± S.D. of three independent experiments. g Paraffin-embedded sections of control or treated tumor tissues from mice were analyzed by
CD31 IHC staining. Scale bar = 25 μm. h Quantitative analysis of CD31 staining corresponding to the images in g. Data represent the mean ± S.D.
of three independent experiments. The ** indicates significance different. The *** indicates extremely significance different
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Tumor bearing mice were treated by oral administration
of PMS. There are not many studies on the PMS dose of
oral administration in mice. In the most researches, the
whole herb was give, such as Plantago asiatica decoction.
Rats were orally administered with the dose of 10 g/kg of
Plantago asiatica in an Pharmacokinetics of plantamajo-
side from Plantago asiatica [18]. Based on the total body
surface area of the mouse, using 0.14 as the conversion
factor [33], mice should be given 14 g/kg Plantago asiatica.
And the content of PMS in the whole herb was about 0.03
[34], so the dose of PMS given mouse should be 420 mg/
kg. What’s more, other report said no chronic toxicity was
observed for plantamajoside concentrate even at a dose of
2000 mg/kg intragastrically in rats [35], this dose may
reach 2800 mg/kg in mouse. However, the higher dose of
PMS was 40 mg/kg(56 mg/kg in mouse) in an study on
nephroprotection of PMS in rats [19]. So we compro-
mised choose the dose 200 mg/kg, and get significant
results. After necropsy, we found that PMS inhibits the
lungs metastasis of 4T1 tumor cells (Fig. 6). According to
the starting point of the current research—inhibiting
MMP activity, and studies have shown that MMP control
the angiogenic switch [36]; as it’s widely known that
angiogenesis and tumor metastasis are closely related [37].
In breast cancer, many secretory or cell surface proteins
implicated in cell homing to bone, angiogenesis, invasion,
and osteoclast recruitment influence the tumor micro-
environment in favor of metastasis [38], so we explore the
mechanism of PMS inhibition by detecting angiogenesis.
CD31 can be used as a marker of density of microvessel
[39]. As Fig. 6 shows, the expression of CD31 by IHC
staining has significant differences between control groups
and PMS treatment group. PMS significantly decreased
vascular density in 4T1 tumor.
We first demonstrated the antitumor effect of PMS,
and it is likely to be achieved by decreasing angiogenesis
which may be regulated by MMP9 and MMP2 activity.
Further identification should be done to determine the
exact mechanism of the inhibition of PMS. Generally,
Chinese herbal medicine is applied as a component of
adjuvant therapy for cancer. In our study, PMS was used
as a single anti-tumor agent and expressed anticancer
effect. In sum, PMS is a promising therapeutic agent for
breast cancer, though its effectiveness on tumor inhibition
combined with other chemotherapeutic agents should be
explored.
Conclusions
Our results not only pointed out that PMS significantly
restricted allograft tumor growth at the concentrations
chosen, but also demonstrate that the inhibition effect of
PMS on MMP9/MMP2 activity may contribute to its
anti-tumor effects.
Additional files
Additional file 1: Table S1. The molecular docking of different agents
with MMP9. Molecular docking of Catechin, Chrysophanol,Phlorizin,
Salidroside, Curcumin, Isoacteoside, Silymarin, Echinacoside, Gastrodin,
Harpagoside with MMP9. All of ΔG are higher than -10.38 cal/mol(the ΔG
of PMS with MMP9). (PPTX 50 kb)
Additional file 2: Figure S1. Different agents affect the activity of
MMP9. Detected IOD of substrate activated by MMP9 treated with
solvent or these ten agents. Data represent the mean ± S.D. of three
independent experiments. (PPTX 106 kb)
Additional file 3: Figure S2. Cell viability decreased after treatment of
Catechin and PMS cannot change the cell viability of CHO cell line. Cell
viability was analyzed using Cell Counting Kit 8 at 0, 12, 24, 36, 48 h after 25,
50, 100, 200, 400 μg/m L Catechin treatment in (A) MDA-MB-231 and (B) 4T1
cells. Data represent the mean ± S.D. of three independent experiments. (C)
Colony formation of MDA-MB-231 and 4T1 cells. Cells were treated with
100 μg/mL Catechin for 36 h, followed with crystal violet staining of attached
cells at 10 days. Similar results were obtained from independent experiments.
D PMS has no side effect on CHO. There was no significant change of cell
viability between pre and post 300 μg/ml PMS treatment for 36 h.
(PPTX 982 kb)
Additional file 4: Figure S3 Catechin shows no inhibition effects on
migration and invasion of MDA-MB-231 or 4T1 cells and no inhibition the
activity of MMP2 and MMP9. Effect of Catechin on cellular migration by
wound assay.(A) Confluent monolayers of cells were culture with solvent
and with 200 μg/ mL Catechin and the migration was evaluated by
wound assay at 36 h. Scale bar = 100 um. (B) The analysis of % open
wound area was performed by the Tscratch software corresponding to
the images in A. Data represent the mean ± S.D. of three independent
experiments. C–E. Effect of Catechin on cellular invasion by transwell
assay. (C) Cells were cultured with solvent or with 100, 200 μg/mL
catechin onto the upper well coated with Matrigel. After 36 h treatment,
cells passed though the Matrigel into the lower well were stained and
counted. Scale bar = 25um (D) and (E) Analysis the % of invasion in
comparison with control cell(100 %) corresponding to the images in C.
Data represent the mean ± S.D. of three independent experiments. F. The
activity of MMP9 and MMP2 secreted by MDA-MB-231 and 4T1 cells kept
same after Catechin treating in vitro. The effect of Catechin on MMP
activity was tested by in gel zymography assay. Cells were cultured onto
6-well plates with solvent and. After 36 h treatment, cell supernatant was
collected and performed Zymography. Similar results were obtained from
independent experiments. (PPTX 1293 kb)
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